Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT ID: NCT00122317
Last Updated: 2018-03-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
187 participants
INTERVENTIONAL
2005-05-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
NCT00438789
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
NCT05886244
Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
NCT04469465
A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03181633
Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT01335165
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eculizumab
600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
eculizumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
eculizumab
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* TRIUMPH patients who have discontinued receiving investigational drug prior to the last visit of the study due to lack of efficacy or exacerbation of symptoms of PNH and have completed all monthly safety and efficacy procedures
* Patient must be willing and able to give written informed consent
* Patient must avoid conception during the trial
Exclusion Criteria
* Patients who have terminated early from the TRIUMPH study due to an adverse event
* Female who is pregnant, breast feeding, or intending to conceive during the course of the study
* Any condition that could increase the patient's risk by participating in the study or could confound the outcome of the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexion Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University Medical Center, Division of Hematology
Stanford, California, United States
Hartford Hospital, Cancer Clinical Research Office
Hartford, Connecticut, United States
Cleveland Clinic Florida, Department of Clinical Research
Weston, Florida, United States
Indianapolis University Cancer Center
Indianapolis, Indiana, United States
Johns Hopkins University Medical Center
Baltimore, Maryland, United States
National Heart, Lung, and Blood Institute, National Institutes of Health
Bethesda, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Mayo Clinic, Divison of Hematology
Rochester, Minnesota, United States
Washington University, Department of Internal Medicine/Division of Hematology
St Louis, Missouri, United States
NYU Clinical Cancer Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program
Durham, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thombosis Program
Philadelphia, Pennsylvania, United States
Royal North Shore Hospital, Haematology Department
Saint Leonards, New South Wales, Australia
Princess Alexandra Hospital, Oncology Haematology Radiation Department
Woolloongabba, Queensland, Australia
The Queen Elizabeth Hospital, Haematology/Oncology Department
Woodville South, South Australia, Australia
The Royal Perth Hospital, Department of Haematology/Level 2
Perth, Western Australia, Australia
Royal Melbourne Hospital, Department of Clinical Haematology & Medical Oncology
Parkville, , Australia
Ucl St. Luc, Hematology Department
Brussels, , Belgium
University of Alberta, Cross Cancer Institute
Edmonton, Alberta, Canada
London Regional Cancer Centre, Clinical Research Unit Room C3080
London, Ontario, Canada
Hopital Saint Louis, Centre d'investigation Clinique
Paris, Cedex, France
Universitatsklinikum Essen, Zentrum fur Innere Medizin
Essen, , Germany
Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin
Hanover, , Germany
Universitatskliniken des Saarlandes, Innere Medizin 1
Homburg/Saar, , Germany
Institut fur Klinische Transfusionmedizin und Immunogenetik, Abtlg. Transfusionmedizin des Univ. Ulm
Ulm, , Germany
St. James's Hospital, Cancer Clinical Trial Office
Dublin, , Ireland
Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica
Florence, , Italy
Ospedale San Martino, Department of Hematology
Genova, , Italy
Ospedale Maggiore di Milano, Divisione di Ematologia
Milan, , Italy
Universita degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico
Napoli, , Italy
Ospedale San Bortolo, Divisione di Ematologia
Vicenza, , Italy
UMC St. Radboud, Department of Hematology
Nijmegen, GA, Netherlands
Hospital Clinic i Provincial, Servicio de Hematologia
Barcelona, , Spain
Hospital Universitario Germans Trias I Pujol, Servicio de Hematologia
Barcelona, , Spain
Hospital De La Paz, Servicio de Hematologia
Madrid, , Spain
Stockholm South Hospital, Division of Hematology
Stockholm, , Sweden
Leeds General Infirmary, D Floor Brotherton Wing
Leeds, , United Kingdom
St. George's Hospital, Department of Haematology
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007 Dec 1;110(12):4123-8. doi: 10.1182/blood-2007-06-095646. Epub 2007 Aug 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E05-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.